Seboclear

Quick links to important sections

Seboclear

Treatment option: Periodontal Disease, Zits

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Seboclear

Property Description
Active ingredient Minocycline (as Minocycline hydrochloride)
Form Tablet, Capsule, Topical Foam, Injection
Pharmacological class Semisynthetic Tetracycline Antibiotic
General Purpose Managing conditions involving bacterial growth and inflammation
Origin Semisynthetic derivative

What Type of Medicine is Seboclear and Its Core Composition?

Seboclear is a medicinal preparation whose sole active ingredient is Minocycline, classifying it as a semisynthetic antibiotic of the tetracycline class. The core compound, Minocycline hydrochloride, is a chemical derivative developed from the original, naturally occurring tetracycline compounds. Minocycline is a highly lipophilic agent and a tetracycline derivative known for its high bioavailability and ability to penetrate tissues effectively. The generic formulation is available globally in multiple brands, all containing the same core active ingredient.


Seboclear's Dual Action and General Purpose

The general purpose of Seboclear stems from its unique dual action, which provides both strong antibacterial effects and distinct anti-inflammatory properties. The antibacterial action works by interfering with the bacteria’s vital process of protein synthesis, necessary for their survival and multiplication. Beyond this primary role, Minocycline possesses distinct anti-inflammatory effects by modulating key inflammatory pathways, a characteristic that distinguishes it from earlier, less lipophilic tetracycline formulations. This makes the medicine generally useful for managing problems where symptoms and irritation are driven by the combined effects of bacterial activity and localized tissue inflammation.


Available Forms and Administration Types

Seboclear is available in several diverse pharmaceutical forms, including oral preparations like tablets and capsules, and highly localized preparations such as a topical foam. This variety in dosage forms ensures the Minocycline active ingredient can be delivered appropriately based on the required site of action. The medication can be delivered systemically via the oral route for full-body distribution, or directly to the affected surface via the topical route. For instance, the availability of specialized forms, like a topical foam, represents a modern differentiation for Minocycline. The composition includes the active ingredient along with various inactive components, which form the necessary base/vehicle to stabilize the medicine and facilitate its proper absorption.

Regulatory References

  1. Minocycline: MedlinePlus Drug Information

What side effects are possible with Seboclear?

Possible side effects and safety information

The official safety profile for Minocycline (the active ingredient in Seboclear) is organized by regulatory bodies into categories based on the frequency of occurrence and the physiological system affected. Adverse reactions are classified from Common to Rare based on clinical data and post-marketing surveillance.

Commonly documented adverse reactions often involve the Nervous System (such as dizziness, light-headedness, and headache) and Gastrointestinal Disorders (such as nausea and vomiting). The medicine is also associated with photosensitivity, which is an exaggerated sunburn reaction upon sun exposure.


Serious Adverse Reactions and Systemic Concerns

Although less frequent, certain serious adverse reactions are explicitly highlighted in regulatory labeling due to their clinical significance. These include severe hypersensitivity reactions like DRESS Syndrome (Drug Rash with Eosinophilia and Systemic Symptoms) and Anaphylaxis. Other rare but serious concerns include Hepatotoxicity (severe liver injury), Pseudomembranous Colitis, and the potential for a Lupus-like syndrome or Idiopathic Intracranial Hypertension.


Population and Duration-Related Safety

Official prescribing information includes specific safety constraints related to certain populations. The use of Minocycline in children up to the age of 8 years is associated with the risk of permanent tooth discoloration (yellow-gray-brown) and is contraindicated during this period of tooth development. Furthermore, hyperpigmentation of the skin, nails, and internal tissues is a documented safety pattern associated with long-term exposure to the medication.

The medicine is contraindicated in individuals with a known hypersensitivity to any drug in the tetracycline class.

Overdose and Emergency Response

Overdose and When to Seek Help

Regulatory prescribing information describes the clinical manifestations of a Seboclear (Minocycline) overdose as primarily involving central nervous system and gastrointestinal symptoms. These may include dizziness, light-headedness, vertigo, nausea, and vomiting.


Emergency Actions

In the event of a suspected overdose, immediate medical attention must be sought as mandated by regulatory authorities. If a patient collapses, has a seizure, or has difficulty breathing, Emergency Services must be called. Treatment is restricted to symptomatic and supportive measures because no specific antidote is known for Minocycline. Furthermore, official documentation states that common detoxification procedures like hemodialysis or peritoneal dialysis are not generally effective.


Severe Outcomes and Monitoring

Overdose risk is associated with excessive systemic drug accumulation, which may lead to severe outcomes. These include Pseudotumor Cerebri (Benign Intracranial Hypertension), often presenting with headache and blurred vision. In patients with significantly impaired renal function, accumulation can result in severe metabolic complications such as azotemia and acidosis. Therefore, monitoring of blood laboratory parameters, including creatinine and BUN, may be required. Special consideration is given to infants, who may develop bulging fontanels due to increased intracranial pressure.

Therapeutic Uses of Seboclear

What Seboclear Treats: Main Uses and Benefits

Seboclear is commonly used across conditions presenting with acute episodes and is applied across domains where additional symptomatic support is needed. The medication is generally used in contexts where management of discomfort is required for symptoms related to inflammatory or irritative states.

The medicine is considered relevant for easing inflammatory manifestations of moderate to severe acne vulgaris and papulopustular rosacea. It helps address symptom clusters that create noticeable physiological strain, such as red bumps (papules) and pus-filled pimples (pustules).

Furthermore, Seboclear is used in the treatment of various susceptible bacterial infections, including specific types of respiratory, urinary, and sexually transmitted infections. It is also considered relevant in situations where patients experience limitations with other treatment options. The treatment generally provides support that helps ease the overall symptom burden, which assists with maintaining functional stability and patient comfort.


Quick Fact: Symptom Support for Inflammatory Conditions

Seboclear is commonly used to help with symptoms related to inflammatory or irritative states, providing support that eases the overall symptom burden caused by papules and pustules.

Eligibility and Restrictions for Use

Seboclear (ketoconazole topical) is a medicine approved for application on the skin to address certain conditions. Eligibility for its use is strictly defined by regulatory documents, focusing on populations for whom the risk may outweigh the benefit.

Official Eligibility and Restriction Status

Classification Population/Condition
Contraindicated Individuals with known hypersensitivity or allergy to ketoconazole or any component of the formulation.
Contraindicated Use in the presence of eye infections.
Not Recommended Children under 12 years of age (safety and effectiveness have not been established in this age group).
Special Consideration Pregnancy and Lactation: Use during these periods is generally not recommended unless clearly necessary and prescribed by a healthcare provider, due to limited safety data.
Restriction Should not be applied to open wounds, cuts, burns, or irritated areas of the skin as this may increase absorption or cause irritation.

For most adults over the age of 12 years (or 18 years for some cream formulations), use is permitted, provided none of the stated contraindications or restrictions apply. Due to the very low systemic absorption of topical ketoconazole, the severe liver-related restrictions associated with the oral form of the drug do not apply to Seboclear.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation, such as the U.S. Food and Drug Administration (FDA) Prescribing Information or European Medicines Agency (EMA) Summary of Product Characteristics, is the authoritative source for a medicine's interaction profile. For the specific product name Seboclear, no comprehensive official regulatory monograph or labeled interaction section is publicly available from major governmental health agencies.

Information concerning interactions is generally derived from data on the active ingredients often found in products marketed under similar names, such as coal tar, sulfur, and salicylic acid, which are components recognized in government regulations for over-the-counter dermatological use. However, these regulations pertain to ingredient approval rather than a specific finished product's complete drug interaction profile.

Interactions involving similar products typically focus on potential additive effects when combined with other topical or systemic medications that share similar properties.

Interaction Classification Regulatory Status
Contraindicated Combinations Undocumented in specific regulatory labels for Seboclear
Pharmacokinetic Effects Undocumented in specific regulatory labels for Seboclear
Pharmacodynamic Effects Undocumented in specific regulatory labels for Seboclear

No explicit timing requirements or restrictions specific to food, alcohol, or herbal products are detailed in official government regulatory documents identified for this product name. Consequently, regulatory guidance on interaction severity (e.g., major, moderate, minor) cannot be reported for Seboclear based solely on mandated official labeling.

Mechanism of Action

Seboclear, which may refer to a combination product or a specific active complex, mediates its effect through a multifaceted pharmacodynamic profile involving keratolytic, antifungal, and anti-proliferative actions on the epidermis and adnexa.

The ketoconazole component acts as an imidazole antifungal, functioning as an inhibitor of fungal cytochrome P450 14alpha-demethylase, which catalyzes the conversion of lanosterol to ergosterol. This antagonism blocks ergosterol biosynthesis, disrupting the structural integrity and permeability of the fungal cell membrane, which leads to cellular component leakage and eventual fungal cell death.

Salicylic acid and coal tar exert a keratolytic action. Salicylic acid promotes the desquamation of corneocytes by disrupting the intercellular cement (likely via dissolution of cell-to-cell lipids and keratin aggregation) in the stratum corneum. Coal tar functions as an antimitotic agent, modulating epidermal cell proliferation and exhibiting generalized antiseptic properties, thereby reducing localized microbial colonization. The composite effect is the normalization of epidermal turnover and reduction of accumulated keratinous material.

Dosage and Administration Information

How to Use Seboclear

Seboclear administration is determined by its pharmaceutical form, with routes including Oral and Intravenous (IV) infusion. The regimen is determined by the specific use context and the required release profile, such as immediate- or extended-release formulations.


Official Dosing and Administration Protocol

Usage Context Dosing Regimen Frequency & Duration Special Conditions
General Systemic Use Initial dose of 200 mg, followed by 100 mg maintenance. Total daily dose must not exceed 400 mg. Typically twice daily (every 12 hours) for the required course duration. IV infusion is administered slowly over 60 minutes. Oral dosing may switch from IV use when appropriate for the clinical context.
Extended-Release Oral Doses range from 40 mg up to 135 mg, based on patient weight and specific use. Administered once daily. Treatment duration is often limited to a maximum of 12 weeks for certain conditions. Must be swallowed whole with adequate fluids; do not crush, split, or chew.

Contextual Use Instructions

The medicine may be taken with or without food. For the oral formulations, adequate amounts of fluid are used to reduce the potential for irritation to the esophagus.

Specific population-based dosing limits apply: in patients with renal impairment (creatinine clearance <80 mL/min), the total daily dosage must not exceed 200 mg. Furthermore, the IV formulation requires reconstitution and subsequent dilution into a compatible solution (such as Sodium Chloride Injection) before the slow, controlled infusion is initiated. This procedural structure ensures the standardized application of the medicine.

Recent Clinical Evidence

Research evidence / Overview of Studies for Seboclear

Evidence for Inflammatory Lesions of Acne Vulgaris

The research for Seboclear in acne is primarily built upon Randomized Controlled Trials (RCTs) and Systematic Reviews used in research exploring how symptoms change over time. These studies included adolescents and adults with moderate to severe inflammatory acne and monitored outcomes such as the measurement of total lesion counts and acne severity scores. Studies reported patterns where participants met predefined score thresholds on assessment scales. However, research highlights that evidence quality varies across studies, and comparative evidence is lacking regarding how these findings relate to those involving all other standard treatments.

Evidence for Inflammatory Lesions of Papulopustular Rosacea

Seboclear was evaluated in Phase 3 Randomized Controlled Trials (RCTs), many of which were active- or placebo-controlled studies conducted in adult populations with moderate to severe papulopustular rosacea. Research examined Investigator Global Assessment (IGA) scores and absolute changes in inflammatory lesion counts (papules and pustules). Phase 3 trial reports documented patterns related to the proportion of participants achieving predefined score thresholds on the IGA scale. Evidence is limited in that most studies focus on short-term treatment periods (e.g., 16 weeks), and long-term effects are not fully established regarding the durability of these patterns.

Evidence for Susceptible Bacterial Infections

Seboclear was studied for a foundation of both historical Clinical Trials and decades of Microbiological Susceptibility Studies. Research examined outcomes related to systemic imbalance in patient populations diagnosed with various infections caused by susceptible microorganisms. Studies monitored outcomes such as the clinical resolution rate and the bacterial eradication rate over short, defined time intervals. Data show patterns related to the eradication of susceptible bacteria. The main uncertainty is the emergence of resistant bacterial strains, which was associated with varying responses observed in some studies.

Research Gaps and Areas of Uncertainty

The research exploring symptom changes typically observed responses over defined time intervals, meaning that follow-up durations were limited. Data for certain groups remain insufficient, and long-term effects are not fully established. Studies primarily focused on adolescents and adults, and the results apply only to the populations studied. There is limited information regarding patterns of use in older adults or those with comorbid health conditions. The broader evidence landscape highlights that evidence quality varies across studies, and comparative evidence is lacking.

Frequently Asked Questions (FAQ)

Common questions about Seboclear (FAQ)

Q: How should I dispose of unused or expired Seboclear?

Unused or expired Seboclear should not be discarded in household trash or flushed. Disposal should align with official regulations and guidance, which often advise consulting a healthcare professional. Options may include returning the medication to a drug take-back program or, if one is unavailable, mixing it with an undesirable substance and discarding it in the household trash, as specified by the FDA.


Q: Can Seboclear be taken with alcohol or food?

According to the official product information, oral forms of Seboclear (minocycline) may be taken with or without food. Regulatory documents do not provide specific warnings or restrictions regarding the use of alcohol during treatment with this medication.


Q: What are the different pharmaceutical forms of Seboclear?

Seboclear is available in diverse pharmaceutical forms, as listed in the official product information. These include oral preparations, such as tablets and capsules, as well as a topical foam for application to the skin and an injectable form for intravenous (IV) use.


Q: What should I do if I miss a dose of Seboclear?

Official patient information often describes a standard procedure for a missed dose: if a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the subsequent dose, the missed dose is typically skipped, and the regular schedule is resumed. Regulatory guidelines advise against taking a double dose.


Q: How long does it take for Seboclear to start working for acne?

Studies and official information indicate that effectiveness is evaluated over the full course of treatment. In studies involving inflammatory lesions, changes often began to be observed between 4 and 8 weeks following the start of treatment, with the full clinical effect generally assessed after 12 weeks.


Q: What happens if I stop taking Seboclear suddenly?

Official reports indicate that common side effects, such as dizziness or light-headedness, are often reversible within a few hours to a few days after the medication is discontinued. Due to the nature of antibiotic treatment, official labeling advises that treatment should be stopped only under the guidance of a healthcare provider.


Q: What is the difference between the oral extended-release and immediate-release Seboclear tablets?

The extended-release (ER) form is designed for a slower absorption rate into the body compared to the immediate-release (IR) form. This difference in absorption impacts the concentration of the drug in the bloodstream. Official information indicates the ER form is associated with a lower potential for certain side effects, such as dizziness.


Q: Can I use Seboclear while I am pregnant or breastfeeding?

Official labeling states that the use of Seboclear (minocycline) during pregnancy may cause harm to the developing fetus, including the potential for permanent tooth discoloration and inhibited bone growth. Due to the drug being excreted into human milk, regulatory guidance generally advises against breastfeeding while undergoing treatment with this medication.

How should Seboclear be stored and disposed of?

How to Store and Dispose of Seboclear (Minocycline)

Storage and disposal requirements for Seboclear are defined by its pharmaceutical form, based on official regulatory labeling.

Mandatory Storage Conditions

Dosage Form Temperature Requirement Environmental Protection
Oral Forms (Capsules/Tablets) Store at Controlled Room Temperature (20°C to 25°C). Protect from light, moisture, and freezing.
Topical Foam Store below 25°C (77°F) after dispensing. Protect from fire, flame, and temperatures above 49°C (120°F).

All forms of the medicine must be kept in the container it came in, tightly closed, and stored out of the sight and reach of children.

Disposal and Stability

The topical foam must be discarded 90 days after it is dispensed. Unused or expired Seboclear should not be thrown in household trash or flushed; disposal should follow instructions from a healthcare professional, preferably via a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Seboclear found in:

A-Z Index: